Based on these preclinical data, anti-TIGIT mAbs are being investigated in several phase 1/2 clinical trials, either as monotherapy or in combination with anti-PD-1/PD-L1 Abs or chemotherapy, for the treatment of malignant lymphoma and MM [50, 51]. This evidence concerns the gene CD274 and Miyoshi myopathy.